CN101461790B - 一种拉米夫定片剂及制备方法 - Google Patents
一种拉米夫定片剂及制备方法 Download PDFInfo
- Publication number
- CN101461790B CN101461790B CN2009101160308A CN200910116030A CN101461790B CN 101461790 B CN101461790 B CN 101461790B CN 2009101160308 A CN2009101160308 A CN 2009101160308A CN 200910116030 A CN200910116030 A CN 200910116030A CN 101461790 B CN101461790 B CN 101461790B
- Authority
- CN
- China
- Prior art keywords
- lamivudine
- tablet
- portions
- weight portion
- microcrystalline cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 title claims abstract description 43
- 229960001627 lamivudine Drugs 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 14
- 239000011734 sodium Substances 0.000 claims abstract description 14
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 14
- 229920002472 Starch Polymers 0.000 claims abstract description 13
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 13
- 239000008107 starch Substances 0.000 claims abstract description 13
- 235000019698 starch Nutrition 0.000 claims abstract description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 7
- 239000008187 granular material Substances 0.000 claims description 15
- 229960003943 hypromellose Drugs 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- YLEQMGZZMCJKCN-NKWVEPMBSA-N [[(2r,5s)-5-(4-amino-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)SC1 YLEQMGZZMCJKCN-NKWVEPMBSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940098312 lamivudine 100 mg Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108700024845 Hepatitis B virus P Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种拉米夫定片剂及制备方法，解决了目前依靠国外公司提供拉米夫定价格昂贵的问题。一种拉米夫定片剂由下列重量份的原料组成：拉米夫定100份、微晶纤维素90～110份、羧甲基淀粉钠15～25份、羟丙甲纤维素1～5份、硬脂酸镁1～5份、50％乙醇90～110份。本发明原料来源方便，价格低廉，生产过程简单，操作便捷，容易将具有活性成分的主药拉米夫定加工成符合药品标准的片剂，本发明的制备方法工艺简单易行，产品质量稳定可控。
Description
技术领域
本发明涉及一种拉米夫定片及其制备方法。
背景技术
拉米夫定(Lamivudine)，其化学名称为(2R-顺式)-4-氨基-1-(2-羟甲基-1，3-氧硫杂环戊-5-基)-1H-嘧啶-2-酮
其化学结构式如下：
分子式：C8H11N3O3S
分子量：229.26
拉米夫定是核苷类抗病毒药。对体外及实验性感染动物体内的乙型肝炎病毒(HBV)有较强的抑制作用。拉米夫定可在HBV感染细胞和正常细胞内代谢生成拉米夫定三磷酸盐，它是拉米夫定的活性形式，既是HBV聚合酶的抑制剂，亦是此聚合酶的底物。拉米夫定三磷酸盐渗入到病毒DNA链中、阻断病毒DNA的合成。拉米夫定三磷酸盐不干扰正常细胞脱氧核苷的代谢，它对哺乳动物DNA聚合酶α和β的抑制作用微弱，对哺乳动物细胞DNA含量几乎无影响。拉米夫定对线粒体的结构、DNA含量及功能无明显的毒性。对大多数乙型肝炎患者的血清HBVDNA检测结果表明，拉米夫定能迅速抑制HBV复制，其抑制作用持续于整个治疗过程，同时使血清氨基转移酶降至正常。长期应用可显著改善肝脏坏死炎症性改变，并减轻或阻止肝脏纤维化的进展。
拉米夫定口服吸收良好而迅速，成人口服拉米夫定0.1g约1小时达血峰浓度，生物利用度达80％～85％，HBV感染的肝细胞代谢为三磷酸拉米夫定，对正常的DNA多聚酶没有活性，而且不会与线粒体DNA相结合，对哺育动物DNA聚合酶的抑制作用微弱，对哺育动物DNA含量及功能无明显影响，病人可长期服用。
拉米夫定目前是治疗乙肝的首选药物，自投放市场以来一直作为抗病毒的一线用药。拉米夫定原料是需要通过制成合适的剂型才能使用或方便服用，由于我国拥有庞大的乙肝患者人群，目前主要依靠国外公司提供的拉米夫定远远不能满足各方面的需求，而且价格昂贵，给病人造成严重的经济负担。
发明内容
为了解决目前依靠国外公司提供拉米夫定价格昂贵的问题，本发明提供一种质量可控、价格低廉的拉米夫定片剂及制备方法。
实现上述目的的技术解决方案如下：
一种拉米夫定片剂由下列重量份的原料组成：
拉米夫定100份、微晶纤维素90～110份、羧甲基淀粉钠15～25份、羟丙甲纤维素1～5份、硬脂酸镁1～5份、50％乙醇90～110份。
上述拉米夫定片剂的制备方法包括下列工艺步骤：
(1)称取上述重量份的拉米夫定、微晶纤维素、羧甲基淀粉钠分别过100目筛；
(2)将微晶纤维素与拉米夫定混合均匀，得混合料；
(3)称取上述重量份的50％乙醇、羟丙甲纤维素搅拌均匀，作为粘合剂加入步骤(2)制得的混合料中，制成软材，过20目筛制成颗粒，置于烘箱中65℃以下干燥得干颗粒；
(4)将干颗粒过20目筛网进行整粒；
(5)在整粒中加入上述重量份的硬脂酸镁、羧甲基淀粉钠混合均匀，得混合粒；
(6)将混合粒置压片机上压制成片；
(7)检验合格后包装成品。
本发明的有益技术效果是：本发明所述的拉米夫定片剂由活性成分拉米夫定(Lamivudine)、稀释剂微晶纤维素(Microcrystalline Cellulose)、崩解剂羧甲基淀粉钠(Carboxymethylstarch Sodium)、润滑剂硬脂酸镁(Magnesium Stearate)和粘合剂50％乙醇(50％ Alcohol)、羟丙甲纤维素(Hypromellose)制成，选用上述物料来源方便，价格低廉，生产过程简单，操作便捷，容易将具有活性成分的主药拉米夫定加工成符合药品标准的片剂；本发明的制备方法工艺简单易行，产品质量稳定可控，其溶出度高，二十分钟内，拉米夫定基本上全部溶出。
具体实施方式
下面结合实施例，对本发明作进一步地描述。
实施例1
取下列原料：拉米夫定100g、微晶纤维素90g、羧甲基淀粉钠15g、羟丙甲纤维素1g、硬脂酸镁1g、50％乙醇90g。
拉米夫定片剂的制备方法包括下列工艺步骤：
(1)称取上述重量份的拉米夫定、微晶纤维素、羧甲基淀粉钠分别过100目筛；
(2)将微晶纤维素与拉米夫定混合均匀，得混合料；
(3)称取上述重量份的50％乙醇、羟丙甲纤维素搅拌均匀，作为粘合剂加入步骤(2)制得的混合料中，制成软材，过20目筛制成颗粒，置于烘箱中65℃以下干燥得干颗粒；
(4)将干颗粒过20目筛网进行整粒；
(5)在整粒中加入上述重量份的硬脂酸镁、羧甲基淀粉钠混合均匀，得混合粒；
(6)将混合粒置压片机上压制成片，可制备拉米夫定片1000片，每片含活性成分拉米夫定100mg；
(7)检验合格后包装成品。
服用方法及剂量：
拉米夫定片通常与其它抗逆转录病毒联合用于HIV感染患者；感染乙型肝炎病毒(HBV)患者，成人剂量，口服，每日一次，每次100mg(活性成分拉米夫定的剂量)。
实施例2：
取下列原料：拉米夫定100g、微晶纤维素100g、羧甲基淀粉钠20g、羟丙甲纤维素3g、硬脂酸镁3g、50％乙醇100g。可制备拉米夫定片1000片，每片含活性成分拉米夫定100mg。其余同实施例1。
实施例3：
取下列原料：拉米夫定100g、微晶纤维素110g、羧甲基淀粉钠25g、羟丙甲纤维素5g、硬脂酸镁5g、50％乙醇110g。可制备拉米夫定片1000片，每片含活性成分拉米夫定100mg。其余同实施例1。
Claims (2)
1.一种拉米夫定片剂，其特征在于由下列重量份的原料组成：
拉米夫定100份、微晶纤维素90～110份、羧甲基淀粉钠15～25份、羟丙甲纤维素1～5份、硬脂酸镁1～5份、50％乙醇90～110份。
2.根据权利要求1所述的一种拉米夫定片剂的制备方法，其特征在于包括下列工艺步骤：
(1)称取上述重量份的拉米夫定、微晶纤维素、羧甲基淀粉钠分别过100目筛；
(2)将微晶纤维素与拉米夫定混合均匀，得混合料；
(3)称取上述重量份的50％乙醇、羟丙甲纤维素搅拌均匀，作为粘合剂加入步骤(2)制得的混合料中，制成软材，过20目筛制成颗粒，置于烘箱中65℃以下干燥得干颗粒；
(4)将干颗粒过20目筛网进行整粒；
(5)在整粒中加入上述重量份的硬脂酸镁、羧甲基淀粉钠混合均匀，得混合粒；
(6)将混合粒置压片机上压制成片；
(7)检验合格后包装成品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101160308A CN101461790B (zh) | 2009-01-09 | 2009-01-09 | 一种拉米夫定片剂及制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101160308A CN101461790B (zh) | 2009-01-09 | 2009-01-09 | 一种拉米夫定片剂及制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101461790A CN101461790A (zh) | 2009-06-24 |
| CN101461790B true CN101461790B (zh) | 2011-04-20 |
Family
ID=40802727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101160308A Active CN101461790B (zh) | 2009-01-09 | 2009-01-09 | 一种拉米夫定片剂及制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101461790B (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953773B (zh) * | 2010-09-10 | 2012-12-26 | 海南美兰史克制药有限公司 | 一种拉米夫定脂质体固体制剂 |
| CN102247332B (zh) * | 2011-01-27 | 2015-03-25 | 济南久创化学有限责任公司 | 一种拉米夫定片及其制备方法 |
| CN102144984B (zh) * | 2011-04-06 | 2012-11-28 | 福建广生堂药业股份有限公司 | 一种易于溶出的拉米夫定片及其制备方法 |
| CN102258497B (zh) * | 2011-08-18 | 2013-01-09 | 海南良方医药有限公司 | 一种拉米夫定片剂组合物及其制备方法 |
| CN102327249B (zh) * | 2011-09-02 | 2013-02-13 | 山东罗欣药业股份有限公司 | 一种拉米夫定片剂组合物及其制备方法 |
| CN103181910B (zh) * | 2011-12-30 | 2015-11-18 | 北京协和药厂 | 一种拉米夫定片剂及其制备方法 |
| CN103705553A (zh) * | 2013-12-25 | 2014-04-09 | 刘亚洲 | 一种治疗乙肝的组合物及其制备方法 |
| CN105943517A (zh) * | 2016-06-01 | 2016-09-21 | 峨眉山通惠制药有限公司 | 一种拉米夫定片剂及均质化生产工艺 |
| CN107961220A (zh) * | 2016-10-19 | 2018-04-27 | 朱隆娅 | 一种拉米夫定片剂及其制备方法 |
-
2009
- 2009-01-09 CN CN2009101160308A patent/CN101461790B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101461790A (zh) | 2009-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101461790B (zh) | 一种拉米夫定片剂及制备方法 | |
| US20170266213A1 (en) | Use of beta-nicotinamide mononucleotide in preparation of anti-aging drugs or health-care products | |
| CN105596646A (zh) | 控制血糖及治疗血脂代谢异常的药品、保健品或食品组合物 | |
| CN104379143A (zh) | 抗癌剂 | |
| CN101199491A (zh) | 拉米夫定片及其制备方法 | |
| CN102144984B (zh) | 一种易于溶出的拉米夫定片及其制备方法 | |
| CN103263433A (zh) | 6-姜烯酚增强胰腺癌对吉西他滨化疗敏感性及其复方药物 | |
| CN101953773B (zh) | 一种拉米夫定脂质体固体制剂 | |
| CN103284953B (zh) | 一种双环醇固体制剂及其制备方法 | |
| CN102512387B (zh) | 扎西他滨药物组合物 | |
| CN110201068B (zh) | 一种克感利咽组合物或制剂在制备防治登革热病药物中的应用 | |
| CN103127028A (zh) | 一种含有富马酸替诺福韦二吡呋酯的胶囊剂 | |
| CN102247332B (zh) | 一种拉米夫定片及其制备方法 | |
| CN104224798B (zh) | 乔木烷型三萜类化合物抗代谢综合征的应用及所制备的药物 | |
| US9084758B2 (en) | Antiviral compositions comprising ethanol extract of Tetracera scandens and use thereof | |
| CN103083339B (zh) | 阿德福韦酯药物组合物 | |
| WO2013138964A1 (zh) | 异瑞香新素化合物在制备抗糖尿病药物中的应用 | |
| CN101199489A (zh) | 双氢青蒿素呱喹片及其制备方法 | |
| CN103181910A (zh) | 一种拉米夫定片剂及其制备方法 | |
| CN101785781B (zh) | 一种左旋氨氯地平或其可药用盐和黑木耳多糖的药物组合物及其应用 | |
| CN101732316A (zh) | 拉米夫定制剂及其制备方法 | |
| CN103908465B (zh) | 一种易于溶出的齐多拉米双夫定片及其制备方法 | |
| CN103845345A (zh) | 肝炎治疗药物 | |
| CN107854448A (zh) | 一种烟酸片及其制备方法 | |
| CN104644576A (zh) | 一种替比夫定口腔崩解片及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20090624 Assignee: Anhui Biochem United Pharmaceutical Co., Ltd. Assignor: Anhui Biochem Bio-Pharmaceutical Co., Ltd. Contract record no.: 2014340000096 Denomination of invention: Lamivudine tablet and preparation method Granted publication date: 20110420 License type: Common License Record date: 20140428 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Lamivudine tablet and preparation method Effective date of registration: 20150428 Granted publication date: 20110420 Pledgee: Agricultural Bank of China, Taihe County, Limited by Share Ltd branch Pledgor: Anhui Beck United Pharmaceutical Co., Ltd.|Anhui Beck Biological Pharmaceutical Co., Ltd. Registration number: 2015990000330 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180522 Granted publication date: 20110420 Pledgee: Agricultural Bank of China, Taihe County, Limited by Share Ltd branch Pledgor: Anhui Biochem United Pharmaceutical Co., Ltd.|Anhui Biochem Bio-Pharmaceutical Co., Ltd. Registration number: 2015990000330 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Lamivudine tablet and preparation method Effective date of registration: 20180523 Granted publication date: 20110420 Pledgee: Agricultural Bank of China, Taihe County, Limited by Share Ltd branch Pledgor: Anhui Biochem United Pharmaceutical Co., Ltd.|Anhui Biochem Bio-Pharmaceutical Co., Ltd. Registration number: 2018340000175 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210618 Granted publication date: 20110420 Pledgee: Agricultural Bank of China Taihe County Limited by Share Ltd. branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: 2018340000175 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A kind of lamivudine tablet and its preparation method Effective date of registration: 20210629 Granted publication date: 20110420 Pledgee: Agricultural Bank of China Taihe County Limited by Share Ltd. branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: Y2021340000011 |